Send us Feedback

Elan Corporation (ELN)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

ELN » Topics » (A) Revenue from Retained Products

This excerpt taken from the ELN 6-K filed Apr 11, 2005.

(A) Revenue from Retained Products

Total revenue from retained products increased to $301.1 million in 2004 from $271.9 million in 2003, an increase of 11%. The increase primarily reflected the growth in prescriptions and demand for Maxipime and Azactam, growth in contract manufacturing and royalties and initial sales of Tysabri. The basic patent on Maxipime expires in March 2007 and the patent on Azactam expires in October 2005. Two U.S. patents covering Maxipime formulations may provide patent protection until 2008. The expiration of these patents is expected to result in generic competition for these products, which could adversely impact future revenues.

As reported by IMS Health National Sales Perspectives, Maxipime prescription demand for 2004 increased by 14% over 2003, while revenues increased from $109.1 million to $117.5 million, or 8%. Azactam prescription demand for 2004 increased by 12% over the same period in 2003, corresponding to increased revenues from $45.1 million to $50.6 million, or 12%. The difference between prescription and revenue growth rates is due to changing wholesaler inventory levels.

 

 

Elan Corporation, plc 2004 Annual Report

31

 


The FDA granted accelerated approval of Tysabri in late November 2004 for the treatment of patients in the U.S. with all forms of relapsing remitting MS. Revenue from Tysabri amounted to $6.4 million in 2004. The marketing and clinical dosing of Tysabri was voluntarily suspended in February 2005.

Contract manufacturing and royalty revenues are as follows:

 

 

 

2004
$m

 

2003
$m

 

% increase/
(decrease)

 

Verelan

 

27.8

 

38.2

 

(27

)%

Diltiazem

 

15.9

 

20.3

 

(22

)%

Skelaxin

 

12.2

 

7.4

 

65

%

Other

 

70.7

 

51.8

 

36

%

Total

 

126.6

 

117.7

 

8

%


Contract manufacturing and royalty revenue comprises revenue earned from products we manufacture for third parties, and royalties we earn on sales by third parties of products that incorporate our technologies. Contract manufacturing and royalty revenues increased 8% from $117.7 million in 2003 to $126.6 million in 2004. The increase was primarily related to additional manufacturing activities. Aside from Verelan, Diltiazem and Skelaxin, no other single product accounted for more than 10% of our contract manufacturing and royalty revenues in either 2004 or 2003.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki